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Abstract
Recent studies have suggested that procalcitonin (PCT) is a safe marker for the discrimination between bacterial and viral infection,
and that PCT-guided treatment may lead to substantial reductions in antibiotic use. The present objective was to evaluate the effect of
a single PCT measurement on antibiotic use in suspected lower respiratory tract infections (LRTIs) in a Danish hospital setting. In a
randomized, controlled intervention study, 223 adult patients admitted to the hospital because of suspicion of LRTI were included
with 210 patients available for analysis. Patients were randomized to either PCT-guided treatment or standard treatment. Antibiotic
treatment duration in the PCT group was based on the serum PCT value at admission. The cut-off point for recommending antibiotic
treatment was PCT ‡0.25 lg/L. Physicians could overrule treatment guidelines. The mean duration of hospital stay was 5.9 days in the
PCT group vs. 6.7 days in the control group (p 0.22). The mean duration of antibiotic treatment during hospitalization in the PCT
group was 5.1 days on average, as compared to 6.8 days in the control group (p 0.007). In a subgroup analysis of chronic obstructive
pulmonary disease patients, the mean length of stay was reduced from 7.1 days in the control group to 4.8 days in the PCT group
(p 0.009). It was concluded that the determination of a single PCT value at admission in patients with suspected LRTIs can lead to
a reduction in the duration of antibiotic treatment by 25% without compromising outcome. No effect on the length of hospital stay
was found.
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Introduction
Lower respiratory tract infections (LRTIs), i.e. community-
acquired pneumonia (CAP), acute exacerbations of chronic
obstructive pulmonary disease (COPD), and acute bronchitis,
are common causes of antibiotic prescription, especially in
primary care [1]. Distinguishing viral from bacterial causes of
disease can be difﬁcult, because clinical presentations of LRTI
due to different causative agents may be similar. Inappropri-
ate use of antibiotics contributes to the development of anti-
biotic-resistant bacteria, and increases both length of stay
and costs of hospitalization [2,3]. Therefore, a routine test
that can safely discriminate between viral and bacterial infec-
tion is needed.
Procalcitonin (PCT) has been suggested as a candidate for
such a test [4]. PCT is the precursor peptide of the hor-
mone calcitonin, and is normally produced by the C-cells of
the thyroid gland; it can also be produced by several cell
types in response to infection, and PCT mRNA has been
found in liver, kidneys, and lungs [5]. Some of the most
potent inducers of PCT are bacterial endotoxins and exotox-
ins, as well as inﬂammatory cytokines (e.g. tumour necrosis
factor-a, interleukin-2, and interleukin-6) [6].
A rise in plasma PCT concentration is seen within 2–4 h
after infection. The rise will continue until appropriate treat-
ment is initiated, or until the infection is well controlled. The
PCT plasma half-life is approximately 24 h [6].
PCT has been studied in various patient populations and
different contexts, e.g. pneumonia, meningitis, urinary tract
infections, pancreatitis, and sepsis [7]. The determination of
PCT levels has been shown to have a higher sensitivity for
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the discrimination between bacterial and viral infections than
that of C-reactive protein (CRP) levels [8], and low serum
PCT levels also accurately predict the absence of bactera-
emia/sepsis in the elderly [9,10].
The increase in plasma PCT in response to infection is
faster than the increase in CRP, and the PCT levels return
to normal faster than those of CRP when the infection is
under control, making the marker advantageous in the early
diagnosis and monitoring of infection [5,8]. Some studies
have shown that PCT levels correlate with mortality in
severely ill patients [11] and that PCT guidance can be
safely used to shorten the duration of antibiotic treatment in
septic patients [12]. Despite abundant literature in favour of
PCT as a biomarker, there is still some controversy about
the clinical usefulness of PCT in the care of critically ill
patients [13], and it is clear that a highly sensitive PCT
assay is necessary for this marker to have a real clinical
impact [14].
Recent studies [4,15] indicate that serum PCT levels can
be used safely to guide antibiotic prescription for LRTIs.
Christ-Crain et al. [4] reported that antibiotic use could be
reduced by approximately 50% when physicians were
encouraged not to prescribe antibiotics for patients with low
serum PCT levels. In another study from the same group
[15], it was demonstrated that PCT determination can be
used safely to guide antibiotic treatment with respect to
duration. Physicians were encouraged to discontinue antibi-
otic treatment when PCT had fallen below a certain prede-
ﬁned cut-off level; this approach resulted in a substantial
reduction in antibiotic use without affecting outcome.
Here, the aim was to assess whether similar results could
be obtained in internal medicine departments without
strong insistence on doctors’ compliance with guidelines
that take PCT levels into consideration. Thus, an attempt
was made to determine the value of a single PCT measure-
ment in routine clinical decision-making and its usefulness
in the reduction of antibiotic consumption and length of
hospital stay of newly admitted patients suspected of
suffering from LRTIs. The physicians’ willingness to take this
new marker into consideration when making their choice of
treatment was also assessed.
Materials and Methods
Setting and study population
This trial was designed as a multicentre, randomized, con-
trolled intervention trial. Adult patients (‡18 years of age)
admitted to the Department of Infectious Diseases at Aarhus
University Hospital, Skejby, the Department of Medicine at
Randers Hospital or the Department of Medicine at
Silkeborg Hospital were assessed for eligibility. The study
inclusion criterion was hospital admission because of suspi-
cion of pneumonia, with one or more clinical symptoms
(cough, expectoration, dyspnoea, or fever >38C). The
assessment of eligibility (i.e. the clinical diagnosis) was made
by the admitting physician, and was based on medical history
and physical examination. Chest X-ray signs of pneumonia
were not required for inclusion in the study.
Eligible patients were randomly assigned to either PCT-
guided treatment or standard care, according to a computer-
generated randomization scheme, and group assignment was
made by the primary investigator. Patients were assigned
numbers according to the order in which test results became
available. Group assignment was concealed until the test
results were available.
Results from patients assigned to the PCT group were
communicated by fax to the respective departments, and
were made available to the physicians making rounds or to
the physicians on call that day. Participating departments and
physicians were not contacted to ensure adherence to guide-
lines. PCT test results were simply provided, and all deci-
sions were left to the treating physicians. In the control
group, serum PCT was measured, but physicians were not
informed of test results, and patients were treated according
to regional guidelines, which recommend benzylpenicillin as
ﬁrst-line treatment for suspected CAP, with treatment dura-
tion of no less than 7 days and depending on clinical
response. For severe infection, cefuroxime and/or clarithro-
mycin is recommended. Clarithromycin is the recommended
ﬁrst-line treatment in cases of suspected atypical infection,
with treatment duration of no less than 14 days.
A standard message without PCT values or recommenda-
tions was sent to the departments/physicians regarding con-
trol patients. Neither participants nor physicians were
blinded to group assignment.
In the PCT group, the physicians were advised to follow a
treatment algorithm [4] based on serum PCT values, as
shown in Fig. 1. Physicians were not asked to wait for PCT
results before initiating antimicrobial therapy; therefore, PCT
values were, in most cases, used to motivate either cessation
or continuation of already initiated treatments. Discontinua-
tion of antibiotic treatment was recommended if PCT at
admission was below 0.25 lg/L, despite delays in test results.
If a patient had already received antibiotic treatment
before determination of the PCT blood level, it was still rec-
ommended that treatment be discontinued at PCT levels
below 0.25 lg/L, but physicians were made aware of the
possibility of infection with atypical agents, which can be
associated with lower PCT values [16–18].
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All diagnostic procedures, therapeutic regimens and ﬁnal
decisions regarding the antibiotic treatment were, in both
groups, left to the discretion of the treating physicians. If a
physician decided to overrule treatment guidelines, he or she
was asked to explain in a short questionnaire.
The study was approved by the local ethics committee
and carried out in accordance with the Helsinki Declaration.
The study was registered in the Clinical Trials Database
(study ID: NCT00415753), and written, informed consent
was obtained from all participants.
Measurement of serum PCT
PCT measurements were performed using a time-resolved
ampliﬁed cryptate emission technology assay (Kryptor PCT;
BRAHMS, Henningsdorf, Germany). This assay has a func-
tional assay sensitivity of 0.06 lg/L, approximately three-fold
to ten-fold above normal mean values [19].
Blood samples for serum PCT measurements were taken
as early as possible, typically upon admission or within 48 h
of admission at most (only seven tests were performed
between 36 h and 48 h after admission); test results were
available on the following day, except for weekends.
PCT analysis was performed at the Department of Clinical
Biochemistry at Aarhus University Hospital, Skejby. Twice a
day, blood samples from Silkeborg and Randers Hospitals
were transported to Aarhus University Hospital, Skejby for
PCT analysis.
If a blood sample could not be analysed within 24 h, the
serum was frozen at 20C until analysis could be performed.
This happened in 41 cases (the same in both groups). Freez-
ing the serum does not affect the accuracy of the PCT analy-
sis (http://www.procalcitonin.com).
Endpoints and statistics
Primary endpoints were antibiotic use (deﬁned as days of
antibiotic treatment during hospitalization) and length of
hospital stay (one night spent in the hospital was counted as
2 days of admission).
The secondary endpoint was the proportion of patients
for whom physicians chose to disregard treatment guidelines.
Endpoints were predeﬁned and analysed on the basis of
intention to treat.
Prestudy power calculations (with 90% power) showed
that 107 patients in each group were necessary to detect a
20% reduction in antibiotic use (from 10 to 8 days), assuming
a two-tailed test and a 5% level of signiﬁcance.
Discrete variables were expressed as counts (percentage),
and continuous variables as means ± standard deviation unless
stated otherwise. Logarithmical transformation was used in
cases of non-normally distributed data; in these cases, the
mean given is the geometric mean with a CI. Comparability of
the PCT group and the control group was analysed using the
chi-square test, two-sample t-test, or non-parametric Mann–
Whitney U-test, as appropriate. A double-sided p-value <0.05
was considered to be signiﬁcant. Linear regression was used
to adjust for differences between groups in the subgroup anal-
ysis of COPD patients. Sensitivity analysis was performed to
adjust for baseline differences between groups.
The statistical analyses were performed using STATA ver-
sion 9.0 (Stata, College Station, TX, USA). The authors held
and analysed all data.
Results
Patients and baseline characteristics
Two hundred and twenty-three patients were included
during the period 1 June 2006 to 30 April 2007, with 210
patients being available for analysis. The trial proﬁle is shown
in Fig. 2.
Baseline characteristics upon admission were similar in
both groups (Table 1). The only signiﬁcant difference
Patients randomized to the PCT group 
Serum PCT < 0.25 μg/L  
Serum PCT 0.25 – 0.50 μg/L 
Serum PCT > 0.5 μg/L 
Antibiotic treatment was discouraged  
Antibiotic treatment was encouraged  
Antibiotic treatment was strongly  
encouraged 
FIG. 1. Treatment algorithm. PCT,
procalcitonin.
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between groups was in coexisting illnesses; seven patients
with cancer were included in the PCT group, and none in
the control group (p 0.006). This difference was adjusted for,
using sensitivity analysis, and it had no inﬂuence on the pri-
mary outcome measures.
A total of three patients died during hospitalization, two
in the PCT group (one due to cancer, PCT 0.3729 lg/L,
and the other due to respiratory failure, PCT 2.905 lg/L)
and one in the control group (due to multi-organ failure,
PCT 9.06 lg/L).
Primary endpoints: antibiotic use and length of hospital stay
Table 2 shows the clinical outcome. Antibiotic treatment
during hospitalization was of signiﬁcantly longer duration in
the control group than in the PCT-guided group.
The mean duration of treatment (when initiated) was
reduced by 25% (95% CI 7–38%) in the PCT group as com-
pared with the control group (p 0.007).
On the day of discharge, 53% of the control group and
54% of the PCT group were still on antibiotics (57/107 in
the control group, and 56/103 in the PCT group).
In the primary analysis, there was no difference in length
of hospitalization. However, in the subgroup of patients with
COPD (n = 89/210), the mean length of stay was 4.8 days
(95% CI 3.8–6.1) vs. 7.1 days (95% CI 5.9–8.5) in the PCT
and control groups, respectively (p 0.009). This subgroup
analysis was adjusted for differences in age and smoking sta-
tus between groups.
Secondary endpoint: treatment according to guidelines
Upon admission, 62% (130/210) of patients presented with a
serum PCT level of <0.25 lg/L, and 21% (45/210) of patients
223 patients admitted because of suspicion of lower 
respiratory infection  
110 patients assigned to 
PCT-guided treatment   





2 no PCT testing 





excluded from    
analysis 
1 no PCT testing 








FIG. 2. Trial proﬁle. PCT, procalcitonin.
TABLE 1. Baseline characteristics of the 210 patients










Age (years, mean ± SD) 67.2 ± 17.6 67 ± 15.6
Male sex 54 (52) 58 (54)
Current or former smoker 68 (66) 82 (77)
Antibiotic treatment prior to
admission
48 (47) 46 (43)
Symptoms
Dyspnoea 69 (67) 74 (69)
Cough 84 (82) 83 (78)
Expectoration 62 (60) 57 (53)
Fever (>38C) 46/99 (46) 47/103 (46)
Pneumonia severity index (PSI)
PSI (mean ± SD) 79.2 ± 27.8 75.8 ± 24.3
PSI class I–III 65 (63) 78 (73)
PSI class IV 35 (34) 27 (25)
PSI class V 3 (3) 2 (2)
Chest X-ray-documented
inﬁltrate
40 (39) 43 (40)
Laboratory ﬁndings
White blood cell count
(·109/L, mean ± SD)
13.2 ± 7.5 12.1 ± 5.9
Procalcitonin
(lg/L, mean ± SD)
2.18 ± 7.6 0.95 ± 3.3
Median PCT (range) 0.14 (0.05–42.13) 0.13 (0.02–30.12)
C-reactive protein
(nmol/L, mean ± SD)
1091 ± 1080 971 ± 1000
Positive blood culture 8/72 (11) 4/79 (5)
Coexisting illness
Congestive heart failure 15 (15) 14 (13)
Cerebrovascular disease 4 (4) 4 (4)
Cancer 7 (7) 0
Diabetes mellitus 13 (13) 11 (10)
COPD 38 (37) 51 (48)
Data are mean ± standard deviation (SD), median (range) or number of patients
(%); because of rounding, percentages may not add up to 100.
COPD, chronic obstructive pulmonary disease.








(n = 107) p-Values
Length of hospital stay in
days, mean (95% CI)
5.9 (5.1–6.9) 6.7 (5.9–7.7) 0.22a
Need for intensive care 7 (7) 5 (5) 0.51b
Death during admission 2 (2) 1 (1) 0.54b
Antibiotics prescribed 88 (85) 85 (79) 0.25b
Durationc of antibiotic
treatment (if initiated)
in days, mean (95% CI)
5.1 (4.4–6.0) 6.8 (5.9–7.7) 0.007a
Final diagnosisd
CAP 47 (46) 50 (47) 0.85b
AECOPD 28 (27) 32 (30)
Acute bronchitis 3 (3) 5 (5)
Acute asthma 2 (2) 3 (3)
Viral infection 2 (2) 2 (2)
Others 21 (20) 15 (14)
Data are geometrical means (95% CI) or number of patients (%); because of
rounding, percentages may not add up to 100.
PCT, procalcitonin; CAP, community-acquired pneumonia; AECOPD, acute
exacerbations of chronic obstructive pulmonary disease.
aAssessed by t-test.
bAssessed by chi-square test.
cDuration of antibiotic treatment during hospital admission.
dAccording to ICD-10.
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with a PCT level of 0.5 lg/L or more. There was no differ-
ence between the groups.
In 41% (42/103) of cases, physicians disregarded the treat-
ment guidelines and continued antibiotic treatment despite a
serum PCT below 0.25 lg/L. The most frequent reasons for
disregarding guidelines were the clinical presentation of the
patient (47%) and late arrival of the test result (41%).
The mean time from blood sampling for PCT determina-
tion until results were available was 1.6 days. In 60% of
cases, the answers were available on the day of testing or
1 day later; in 25% of cases, the answers were not available
until day 3 or later after sampling. The delay in receiving
the PCT results did not correlate with PCT values; that is,
neither a high nor a low PCT value inﬂuenced the extent of
the delay.
Clinical characteristics of 42 patients for whom guidelines
were overruled are shown in Table 3.
Of these 42 patients, 20 were discharged with the diagno-
sis of CAP (in 14 of these cases, there were inﬁltrations on
the chest X-ray), 13 with acute exacerbation of COPD,
three with bronchitis, one with asthma, and ﬁve with other
disorders (including two urinary tract infections). In one of
these patients, there was serological evidence of infection
with Legionella pneumophila, and treatment was appropriately
continued despite a PCT value of 0.098 lg/L.
Fourteen patients were treated with antibiotics despite
low serum PCT levels, low CRP levels, and absence of fever
and chest X-ray-documented inﬁltrate; eight of these patients
had known COPD. These 14 patients were included because
of cough, dyspnoea, or both.
In two cases (in the PCT group), physicians chose to with-
hold antibiotic treatment despite a serum PCT of >0.25 lg/
L. One of these patients (PCT 0.373 lg/L) died 24 days
after admission; he had a metastatic cancer, which was the
probable cause of death. The other patient (PCT 0.297 lg/
L) recovered without treatment, and was discharged after
5 days.
Another two patients (one in each group) died during the
study period; they both had greatly elevated serum PCT
levels upon admission, and received appropriate treatment.
Microbiology
Causative microorganisms were identiﬁed in 15% of cases, at a
similar rate in both groups. The most frequently detected
microorganisms were Streptococcus pneumoniae (4%),
Haemophilus inﬂuenzae (3%), and Mycoplasma pneumoniae (2%).
Other microorganisms were Escherichia coli, L. pneumophila and
Chlamydia pneumoniae. Causative agents were found in blood
or sputum using either culture, PCR, or speciﬁc antibodies.
Discussion
In spite of the fact that the guidelines were overruled in 41%
of the cases, a substantial reduction in length of antibiotic
treatment was achieved by using a single PCT value to guide
the duration of treatment.
The length of treatment was reduced from 6.8 days
(95% CI 5.9–7.7) in the control group to 5.1 days (95% CI
4.4–6.0) in the PCT group; this amounts to a 25% (95% CI
7–38) reduction. The duration of treatment in both groups
was short according to international standards. The reason
for this is that there was no follow-up after discharge, and
therefore only the days of treatment during hospitalization
were counted. Had the days of antibiotic use after discharge
been counted, there would, of course, have been a longer
apparent duration of treatment in both groups. As this
would have inﬂuenced both groups similarly, there should
not have been any particular impact on the difference
between the groups.
No signiﬁcant differences regarding the length of stay
were found between the two groups; the mean duration of
hospital stay was 5.9 days (95% CI 5.1–6.9) in the PCT
group vs. 6.7 days (95% CI 5.9–7.7) in the control group
(Table 2). The study did not have the power to detect a
minor reduction in length of stay. It is thus hypothesized that
the trend towards shorter stay in the PCT group represents
a minor effect on this outcome. There was indeed a signiﬁ-
cant difference in length of hospitalization in a non-planned
subgroup analysis of COPD.
TABLE 3. Characteristics of procalcitonin (PCT) group








(n = 22) p-Values
PCT <0.1 lg/L 13 (31) 15 (68) 0.004a
CRP >1000 nmol/L 15 (36) 0 (0) 0.001a
WBC count >11 · 109/L 21 (50) 6 (27) 0.067a
Fever >38C 18/41 (44) 8/20 (40) 0.77a
Chest X-ray inﬁltrate 16 (38) 1 (5) 0.004a
Dyspnoea 31 (74) 14 (64) 0.40a
Respiratory frequency
>30/min
7/40 (18) 2/21 (10) 0.40a




5.1 (4.1–6.2) 4.2 (3.0–6.0) 0.33b
COPD 16 (38) 11 (50) 0.36a
Data are number of patients (%) or geometrical means (95% CI).
CRP, C-reactive protein; WBC, white blood cell; COPD, chronic obstructive
pulmonary disease.
aAssessed by chi-square test.
bAssessed by t-test.
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Low adherence to guidelines on the part of physicians was
documented; in 41% of cases, the physicians chose to over-
rule the treatment guidelines. In most cases, this was because
of the clinical presentation of the patients. It seems that con-
ventional signs of infection (e.g. fever and elevated CRP level)
were considered to be more important in the clinical setting,
supported by the fact that, in the group of patients with
serum PCT <0.25 lg/L, there were signiﬁcant differences in
CRP levels and frequency of chest X-ray-documented
inﬁltrates between treated and untreated patients (Table 3).
This study had several important limitations. It was not
possible to avoid some delay in PCT analysis, as tests could
not be performed on weekends. In cases where antibiotic
treatment was interrupted on the basis of the PCT value,
the duration of treatment might have been even shorter had
the PCT result been available earlier. Another important lim-
itation was the open intervention trial design, where physi-
cians knew that their treatment decisions were observed.
This could potentially alter the antibiotic prescription rate in
the control group and therefore bias the results towards
null. Finally, only one PCT measurement per patient was per-
formed, which meant that physicians were not given the
chance to re-evaluate patients in the light of clinical changes.
The use of a single PCT measurement may, in fact, be a
strength of this study, as it was shown that a simple and
affordable intervention that is easy to implement in daily clin-
ical practice can lead to a reduction in antibiotic use.
The present ﬁndings are not entirely consistent with those
of Christ-Crain et al. [4], who showed a 40% reduction
in antibiotic prescription with the use of a PCT-guided
approach. The probable reason for the 15% discrepancy is
most likely the physicians’ reluctance to comply with
guidelines; 41% of our patients received continued antibiotic
treatment despite PCT levels <0.25 lg/L. This is in contrast
to only 10.4% of patients in the Christ-Crain study [4].
There may be several reasons for this; the present multi-
centre setting probably made it more difﬁcult to enlist
support and collaboration than a single-centre design.
However, because of this, the present study may more
closely approximate the routine clinical setting.
A major difference between the present study and that of
Christ-Crain et al. is that PCT analysis was performed only
once daily and not on weekends, and it would not have been
ethical to withhold treatment until a result had been
obtained. No difference in antibiotic prescription rates
between the two groups was seen. However, physicians
were asked to discontinue treatment if PCT levels were
below the cut-off level.
A recently published study [20], including 219 patients and
no controls, reported that PCT guidance in the treatment of
LRTIs could be helpful in reducing antibiotic prescription,
but not to the extent found by Christ-Crain et al. [4]. In that
study [20], which was based on the implementation of rou-
tine PCT testing in a normal clinical setting, antibiotic treat-
ment was continued despite serum PCT levels <0.25 lg/L in
34.7% of patients, a ﬁgure much closer to the 41% found in
this study. These ﬁndings are in support of PCT having a role
in the management of LRTIs and in the reduction of antibi-
otic use in patients with LRTI, but it seems that strict
enforcement of guidelines is necessary if the use of this mar-
ker is to have a maximal effect on antibiotic usage.
In the subgroup of patients with COPD (89/210, 42% of
patients), signiﬁcant differences were found in length of stay,
as well as in mean duration of antibiotic therapy; length of
antibiotic treatment was reduced by 40% (95% CI 17–57%)
and length of stay by 32% (95% CI 9–49%).
These ﬁndings are in agreement with a recent study con-
cerning PCT and acute exacerbation of COPD [21], which
showed a >30% reduction in antibiotic use with PCT guid-
ance, without differences in outcome. In light of this, it
seems that PCT might have a promising role in the manage-
ment of COPD patients. Further studies in this area are
needed.
A recent study [22] has shown that a 3-day intravenous
antibiotic treatment is not inferior to an 8-day treatment in
mild to moderate/severe CAP. This ﬁnding, together with
those of Christ-Crain et al. [4,15] and those of the present
study, may further augment data supporting the effectiveness
and safety of shorter antibiotic treatments.
It is thus concluded that the consideration of a single PCT
value determined at admission in patients with suspected
LRTIs led to a reduction in the duration of antibiotic therapy
by 25%, without adverse effects. In COPD patients the
reduction was even greater, with a similar effect on the
length of hospital stay. Physicians still rely mostly on more
conventional markers and signs of infection. Strict adherence
to guidelines is therefore likely to enhance the correct use
of PCT-guided treatment.
Larger multicentre studies, with close resemblance to daily
clinical practice, are needed to further clarify the role that
PCT determinations may have in the management of COPD
patients.
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